Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b open-label single-arm study of zanidatamab in HER2-amplified biliary tract cancer
2020-000459-11Phase 2Completed
- Sponsor
- Zymeworks Inc.
- Start
- Jun 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanidatamab in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA) and 1 more, sponsored by Zymeworks Inc. Primary endpoint: Confirmed objective response rate (ORR). Started Jun 2020; status: completed.
02
Drugs
zanidatamab
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on 2020-000459-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000459-11.